


In the Claims

1. (Previously Presented) A diazaspirononane compound having the following formula:

Formula 1



and pharmaceutically acceptable salts thereof,

wherein Q^I is $(CZ_2)_u$, Q^{II} is $(CZ_2)_v$, Q^{III} is $(CZ_2)_w$, and Q^{IV} is $(CZ_2)_x$,


u, v, w and x are individually 0, 1, 2, 3 or 4, preferably 0, 1, 2 or 3,

and the values of u, v, w and x are selected such that the ring is a diazaspirononane,

R is hydrogen, lower alkyl, acyl, alkoxycarbonyl or aryloxycarbonyl,

Z is, individually, selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl and substituted arylalkyl;

Cy is a six membered ring of the formula:



where one of X, X', X'', X''' and X'''' is nitrogen, and the others are carbon bonded to a substituent species,

Atty Dkt. No. T103 1530.1

wherein "substituent species" are, individually, selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, halo, -OR', -NR'R'', -CF₃, -CN, -NO₂, -C₂R', -SR', -N₃, -C(=O)NR'R'', -NR'C(=O)R'', -C(=O)R', -C(=O)OR', -OC(=O)R', -O(CR'R'')_rC(=O)R', -O(CR'R'')_rNR''C(=O)R', -O(CR'R'')_rNR''SO₂R', -OC(=O)NR'R'', -NR'C(=O)OR'', -SO₂R', -SO₂NR'R'', and -NR'SO₂R'',

where R' and R'' are individually hydrogen, C₁-C₈ alkyl, cycloalkyl, aryl, or arylalkyl, and r is an integer from 1 to 6, or R' and R'' can combine to form a cyclic functionality, and

wherein the term "substituted" as applied to alkyl, aryl, cycloalkyl and the like refers to the substituents described above, starting with halo and ending with -NR'SO₂R''.

Claims 2-3. (Cancelled)

4. (Previously Presented) The compound of claim 1, wherein X''' is nitrogen.

Claim 5. (Cancelled)

6. (Original) The compound of claim 1, wherein X, X'' and X''' are carbon bonded to a substituent species.

7. (Original) The compound of claim 6, where the substituent species at X, X'' and X''' are hydrogen.

Claims 8-10. (Cancelled)

11. (Previously Presented) A pharmaceutical composition including a compound of claim 1 along with a pharmaceutically acceptable carrier.

Claims 12-40. (Cancelled)

41. (currently Amended) A compound selected from the group consisting of:

7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane

~~7-(5-pyrimidinyl)-1,7-diazaspiro[4.4]nonane~~

~~7-(5-isoxazolyl)-1,7-diazaspiro[4.4]nonane~~

~~7-(5-isothiazolyl)-1,7-diazaspiro[4.4]nonane~~

~~7-(5-(1,2,4-oxadiazolyl)-1,7-diazaspiro[4.4]nonane~~

~~7-(2-(1,3,4-oxadiazolyl)-1,7-diazaspiro[4.4]nonane~~

~~7-(2-pyrazinyl)-1,7-diazaspiro[4.4]nonane~~

~~7-(3-pyridazinyl)-1,7-diazaspiro[4.4]nonane~~

7-(5-methoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane

7-(5-cyclopentyloxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane

7-(5-phenoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane

7-(5-(4-hydroxyphenoxy)-3-pyridyl)-1,7-diazaspiro[4.4]nonane

7-(5-ethynyl-3-pyridyl)-1,7-diazaspiro[4.4]nonane

7-(6-chloro-3-pyridyl)-1,7-diazaspiro[4.4]nonane

~~7-(6-methoxy-3-pyridazinyl)-1,7-diazaspiro[4.4]nonane~~

1-(3-pyridyl)-1,7-diazaspiro[4.4]nonane

~~1-(5-pyrimidinyl)-1,7-diazaspiro[4.4]nonane~~

~~1-(5-isoxazolyl)-1,7-diazaspiro[4.4]nonane~~

~~1-(5-isothiazolyl)-1,7-diazaspiro[4.4]nonane~~

~~1-(5-(1,2,4-oxadiazolyl)-1,7-diazaspiro[4.4]nonane~~

~~1-(2-(1,3,4-oxadiazolyl)-1,7-diazaspiro[4.4]nonane~~

~~1-(2-pyrazinyl)-1,7-diazaspiro[4.4]nonane~~

Atty Dkt. No. T103 1530.1

~~1-(3-pyridazinyl)-1,7-diazaspiro[4.4]nonane~~
1-methyl-7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane
~~1-methyl-7-(5-pyrimidinyl)-1,7-diazaspiro[4.4]nonane~~
~~1-methyl-7-(5-isoxazolyl)-1,7-diazaspiro[4.4]nonane~~
~~1-methyl-7-(5-isothiazolyl)-1,7-diazaspiro[4.4]nonane~~
~~1-methyl-7-(5-(1,2,4-oxadiazol)yl)-1,7-diazaspiro[4.4]nonane~~
~~1-methyl-7-(2-(1,3,4-oxadiazol)yl)-1,7-diazaspiro[4.4]nonane~~
~~1-methyl-7-(2-pyrazinyl)-1,7-diazaspiro[4.4]nonane~~
~~1-methyl-7-(3-pyridazinyl)-1,7-diazaspiro[4.4]nonane~~
1-methyl-7-(5-methoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(5-cyclopentyloxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(5-phenoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(5-(4-hydroxyphenoxy)-3-pyridyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(5-ethynyl-3-pyridyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(6-chloro-3-pyridyl)-1,7-diazaspiro[4.4]nonane
~~1-methyl-7-(6-methoxy-3-pyridazinyl)-1,7-diazaspiro[4.4]nonane~~
7-methyl-1-(3-pyridyl)-1,7-diazaspiro[4.4]nonane
7-methyl-1-(5-pyrimidinyl)-1,7-diazaspiro[4.4]nonane
~~7-methyl-1-(5-isoxazolyl)-1,7-diazaspiro[4.4]nonane~~
~~7-methyl-1-(5-isothiazolyl)-1,7-diazaspiro[4.4]nonane~~
~~7-methyl-1-(5-(1,2,4-oxadiazol)yl)-1,7-diazaspiro[4.4]nonane~~
~~7-methyl-1-(2-(1,3,4-oxadiazol)yl)-1,7-diazaspiro[4.4]nonane~~

~~7-methyl-1-(2-pyrazinyl)-1,7-diazaspiro[4.4]nonane~~
~~7-methyl-1-(3-pyridazinyl)-1,7-diazaspiro[4.4]nonane~~
2-(3-pyridyl)-2,7-diazaspiro[4.4]nonane
~~2-(5-pyrimidinyl)-2,7-diazaspiro[4.4]nonane~~
~~2-(5-isoxazolyl)-2,7-diazaspiro[4.4]nonane~~
~~2-(5-isothiazolyl)-2,7-diazaspiro[4.4]nonane~~
~~2-(5-(1,2,4-oxadiazol)yl)-2,7-diazaspiro[4.4]nonane~~
~~2-(2-(1,3,4-oxadiazol)yl)-2,7-diazaspiro[4.4]nonane~~
~~2-(2-pyrazinyl)-2,7-diazaspiro[4.4]nonane~~
~~2-(3-pyridazinyl)-2,7-diazaspiro[4.4]nonane~~
2-(5-methoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-(5-cyclopentyloxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-(5-phenoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-(5-(4-hydroxyphenoxy)-3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-(5-ethynyl-3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-(6-chloro-3-pyridyl)-2,7-diazaspiro[4.4]nonane
~~2-(6-methoxy-3-pyridazinyl)-2,7-diazaspiro[4.4]nonane~~
2-methyl-7-(3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-methyl-7-(5-methoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-methyl-7-(5-phenoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane
6-(3-pyridyl)-1,6-diazaspiro[3.5]nonane
1-methyl-6-(3-pyridyl)-1,6-diazaspiro[3.5]nonane
2-(3-pyridyl)-2,5-diazaspiro[3.5]nonane

Atty Dkt. No. T103 1530.1

5-methyl-2-(3-pyridyl)-2,5-diazaspiro[3.5]nonane and
pharmaceutically acceptable salts thereof.

Claim 42. (Cancelled)

43. (Previously Presented) A pharmaceutical composition comprising an effective
amount of a compound of claim 41 along with a pharmaceutically acceptable carrier.

Claim 44. (Cancelled)